Seven doses of HLA-A24- or A02-restricted WT1 peptide (1-3mg) emulsified with 0.5-2KE of adjuvant will be intradermally injected on bilateral axillary and inguinal areas every 2 weeks. WT1 peptide d

2 trials

Sponsors

Shinshu University, Nagano Children's Hospital

Conditions

Pediatric cancersPediatric refractory solid tumors or leukemia

Phase 1

Phase I clinical trial of WT1 peptide vaccine therapy for pediatric cancers

Active, not recruitingJPRN-UMIN000011030

Shinshu UniversityPediatric cancers

Start: 2013-07-01Target: 15Updated: 2026-06-29

Unknown Phase

Phase 1 clinical trial of WT1 peptide vaccine therapy for pediatric cancers.

Active, not recruitingJPRN-UMIN000027867

Nagano Children's HospitalPediatric refractory solid tumors or leukemia

Start: 2017-06-27Target: 15Updated: 2026-06-29